Personalized Health Company Establishes Medical Advisory Board; Set to Conduct First Clinical Trials
NASA Ames Research Center, Moffett Field, CA - November 12, 2013 - Scanadu, a personalized health electronics company working to make this the last generation to know so little about our health, today announced it has received $10.5 million in Series A funding. Relay Ventures led the round of funding with participation from Tony Hsieh’s VegasTechFund, Jerry Yang’s Ame Cloud Ventures and others with a track record in building disruptive companies of great value in the mobile, cloud, consumer and healthcare industries. This new round of funding will be used to support Scanadu’s go-to market strategy and manufacturing, continue its path to FDA approval and add talent to the team. The company also announced that it has formed a Medical Advisory Board and will conduct its first clinical trials at the Scripps Translational Science Institute.
“We focus on backing ambitious entrepreneurs who are using mobile computing to unlock opportunity and create new markets,” said Kevin Talbot, co-founder and managing partner of Relay Ventures. “Walter’s vision for the future of consumer healthcare is profound and Scanadu stands to make a lasting impact on an industry ripe for disruption.”
“Scanadu is right at the heart of the next generation of computing which combines mobility, sensors, cloud and big data,” said Jerry Yang, co-founder of Yahoo! and founding partner of Ame Cloud Ventures. “I am bullish on Scanadu and its potential to revolutionize the way we think about our health.”
In July of this year, Scanadu closed a crowdfunding campaign on Indiegogo that quickly became the most funded campaign in the platform’s history, raising more than $1.6 million. Those who participated in the campaign will be a crucial part of the company’s road to FDA approval by taking part on a voluntary basis in a usability study for the Scanadu Scout™ in 2014.
Other participating investors in the Series A round include Broe Group, Mindful Investors and Redmile Group. With this round, Scanadu has raised $14.7 million in funding to date.
Medical Advisory Board and First Clinical Trials Pave the Way to Market
Furthering the company on its path to market, Scanadu will conduct its first clinical trials for Scanadu Scout™ at the Scripps Translational Science Institute (STSI). Those studies will be conducted as part of the Wired for Health mobile trial, which includes patients who live with diabetes, hypertension and heart arrhythmia. This first baseline study will help design future controlled studies, and will be designed to empower adults via a Scanadu Scout™ to yield optimal blood pressure.
“The era of digital healthcare has arrived,” said Dr. Eric Topol, director of the STSI and chief academic officer for Scripps Health. “We are excited to bring Scanadu to Scripps to further the potential of this technology to improve lives.”
Scanadu’s newly established Medical Advisory Board comprises leaders with deep experience from across the medical, regulatory and research fields. These advisors, listed below, all have a stake in advancing consumer healthcare and will actively advise Scanadu on long-term strategy and facilitate the sharing of knowledge and innovation transfer between Scanadu and the larger research and medical communities.
“We are more determined than ever to make the first medical tricorder a reality,” said Scanadu founder and CEO Walter De Brouwer. “With the experience and expertise of this group of investors and advisors, we know we’re in the right position to take our vision all the way and put FDA approved devices in the hands of consumers.”
Scanadu is developing a portfolio of products that put the experience of an emergency room visit in the palm of your hand. Its first device, the Scanadu Scout™, is a vital sign monitor that analyzes, tracks and trends your vitals - temperature, respiratory rate, oximetry, ECG, systolic blood pressure and diastolic blood pressure - in 10 seconds. The company is also creating a disposable urine analysis testing platform, ScanaFlo, which works with your smartphone to offer a complete urine analysis test in minutes. Once FDA approved, it could also measure for pregnancy complications, pre-eclampisa, gestational diabetes, heart-related kidney problems and urinary tract infections.
The Scanadu Medical Advisory Board includes: • Ms. Megan Moynahan, former Assistant Director for Technology and Innovation at the FDA's Center for Devices and Radiological Health, and current Executive Director of the Institute for Functional Restoration • Jon Mogford PhD, former Deputy Director of the Defense Sciences Office at DARPA and vice chancellor for research for The Texas A&M University System • Dr. Paul A. Sobotka, former Chief Medical Officer Ardian Inc. and professor of medicine, division of cardiology The Ohio State University. • Dr. Jennifer Mieres, cardiologist North Shore-LIJ Health System and professor of cardiology and population health at Hofstra University • Dr. Steven Curley, professor, Department of Surgical Oncology, Baylor College of Medicine • Dr. Alan Greene, chief medical officer, Scanadu, and founding President of the Board of the Society for Participatory Medicine and former member of the clinical faculty at Stanford University School of Medicine • Dr. Brett Mensh, former assistant professor at Columbia University and research scientist at MIT
About Scanadu Based at NASA-Ames Research Center, Scanadu is using mobile and sensor technology to make the first medical tricorder and ensure this is the last generation to know so little about our health. Unveiled in November 2012, the company is developing a portfolio of FDA approved, consumer friendly products that put the experience of an emergency room in the palm of your hand. The portfolio includes the Scanadu Scout™ vital sign monitor and ScanaFlo, a urine analysis test. In July 2013, Scanadu became the most funded campaign on Indiegogo, enlisting supporters to be a part of the first usability study and then clinical studies for the company’s road to FDA approval. Scanadu was founded by Walter de Brouwer in 2011 and is competing in the Qualcomm Tricorder X Prize. For more information visit www.Scanadu.com.
Company Launches Indiegogo Campaign to Begin Building the Future Global Body of Health Data
NASA Ames Research Park, Moffett Field, CA - May 22, 2013 - Scanadu, a personalized health electronics company participating in the Qualcomm Tricorder X PRIZE, today announced it is one step closer to bringing the first medical tricorder™ to life. In addition to unveiling updates and refinements to Scanadu Scout™ and ScanaFlo™, the company has also launched an Indiegogo campaign, inviting supporters to reserve a first-edition Scanadu Scout™ and contribute to building the future global body of health data.
“We are in awe at the enthusiasm the community has shown for the Scanadu Scout since the prototype was first revealed six months ago. We get calls and emails everyday from parents, researchers, students and body hackers anxious to be part of the first generation of consumers to truly understand their own health,” said Scanadu Founder and CEO Walter de Brouwer. “We’ve pushed the envelope, had some key breakthroughs, and are ready to share this next iteration of the product with consumers.”
Scanadu Scout is a vital sign monitor that analyzes, tracks, and trends your vitals - temperature, respiratory rate, oximetry, ECG, systolic blood pressure, diastolic blood pressure, and stress - in 10 seconds. With encouraging feedback from the community, partners, and regulators, and a strong push from Scanadu’s engineers and researchers, the company has made three key breakthroughs:
Just like Spock, you can now scout someone else - an ailing parent or sick child. With this breakthrough, Scanadu made some key changes to the design. It is now circular in shape, with the sensors built into the front of the device.
You’ll be able to collect readings from Scanadu’s suite of products - including ScanaFlo - through a single integrated app. Seeing your comprehensive healthfeed allows for data fusion, and the potential to read more vitals such as cuffless, non-invasive blood pressure.
Increased computational power
Scanadu has added more horsepower to the device, taking it from 8-bit (the power of an Apple II) to 32-bit (the power of a smartphone). The new device is built on Micrium, NASA’s real-time operation system for SAM (Sample Analysis at Mars) on the Rover Curiosity.
The company also announced updates today to ScanaFlo, a low-cost tool that uses the smartphone as a urine analysis reader, and unveiled the first design of the product. The small white, disposable paddle with multi-colored test strips and a QR code built into the device tests for levels of glucose, protein, leukocytes, nitrates, blood, bilirubin, urobilinogen, specific gravity, and pH in urine. It will also test for pregnancy.
Scanadu has received its first batch of 6,000 paddles and is ready to begin clinical trials. The company anticipates submitting a 510(k) application to FDA in the beginning of July 2013. “Today’s urine tests are really hard to use and the results are not easy to interpret,” said Aaron Rowe, research director at Scanadu. “ScanaFlo will make it simple for pregnant women to monitor themselves for complications between appointments with their doctor.”
Lastly, starting today, supporters can reserve a first-edition Scanadu Scout on Indiegogo and be part of the exploratory community bringing to life the vision of making this the last generation to know so little about our health. As a participant in the Indiegogo campaign, supporters will be able to take part in a usability study and provide feedback on feasibility, usability, and consumer friendliness that will be a valuable part of Scanadu’s road to FDA.
The 30-day campaign will offer a variety of perks including regular updates from Scanadu, a limited edition Scanadu Scout, visits to NASA to spend the day as a citizen astronaut for a space medicine workshop, and a tour of NASA Ames Research Park. Scanadu will offer an early bird special of $149 for the device to the first 1,000 participants. Additional units will be made available at the anticipated retail price of $199. Additionally, two ScanaFlo paddles be included with each Scanadu Scout, which is expected to ship in Q1 2014. The devices on Indiegogo are not FDA approved.
STAR TREK, TRICORDER and related marks and logos are trademarks of CBS Studios Inc. used under license by the X PRIZE Foundation. Scanadu is a participant in the Qualcomm Tricorder X PRIZE competition.
Based at NASA-Ames Research Park, Scanadu is using mobile, sensor and social technology to ensure this is the last generation to know so little about our health. In November 2012, the company unveiled its product family consisting of the Scanadu Scout vital sign monitor, ScanaFlo urine analysis test and Project ScanaFlu saliva test. The first products look to disrupt home medicine and will be in market early 2014. Scanadu was founded by Walter de Brouwer in 2010 and is competing in the Qualcomm Tricorder X Prize. For more information visit www.Scanadu.com.
Scanadu Unveils Family of New Tools to Revolutionize Consumer Healthcare
NASA-Based Company Puts a Doctor in Your Pocket
NASA Ames Research Center, Moffett Field, CA - November 29, 2012 - Scanadu, a new personalized health electronics company, today unveiled the first three products in its family of consumer health tools: Scanadu SCOUT, Project ScanaFlu and Project ScanaFlo. Based at NASA-Ames Research Center, Scanadu is using mobile, sensor and social technology to ensure this is the last generation to know so little about our health. The newly introduced home diagnostic tools are set to be the biggest innovation in home medicine since the invention of the thermometer.
Founded in 2010 by Walter de Brouwer after a family medical emergency, Scanadu is using imaging and sound analysis, molecular diagnostics, data analytics and a suite of algorithms to create devices that offer a comprehensive, real-time picture of your health data. The company is also participating in the Qualcomm Tricorder X Prize, which looks to bring healthcare to the palm of your hand, as well as the Nokia Sensing X Challenge, which seeks to revolutionize digital healthcare.
“The thermometer, introduced in the 1800s, was the last great tool to revolutionize home healthcare,” said Walter de Brouwer, founder and CEO of Scanadu. “Consumers don’t have the tools they need to monitor their health and make informed decisions about when they’re actually sick and need to see a doctor. We want to empower consumers to take control of their health and give them direct access to their personal healthfeed.”
Scanadu Product Family
Scanadu SCOUT is a small, speedy and affordable device that puts vital health information at your fingertips. Simply hold Scanadu SCOUT to the temple, and in less than ten seconds it will accurately read more than five vital signs. Data collected by the Scanadu SCOUT is uploaded to the Scanadu smartphone app via Bluetooth to show:
Pulse transit time
Heart rate (pulse rate)
Electrical heart activity
Heart rate variability
Blood oxygenation (pulse oximetry)
“Scanadu SCOUT lets users explore the diagnostic abilities of a clinic and conveniently puts them in your smartphone for less than $150,” said de Brouwer. “It’s like having a doctor in your pocket.”
Scanadu also unveiled its low-cost and disposable early detection diagnostic tools - Project ScanaFlo and Project ScanaFlu - which are integrated with Scanadu’s smartphone app.
Project ScanaFlo is a low-cost tool that uses the smartphone as a urine analysis reader. Designed to be sold over-the-counter as a disposable cartridge, Project ScanaFlo will test for pregnancy complications, preeclampisa, gestational diabetes, kidney failure and urinary tract infections. For pregnant women, Project ScanaFlo will be the first to provide a healthfeed throughout the duration of a pregnancy.
Project ScanaFlu is a low-cost tool that uses the smartphone as a reader to assess cold-like symptoms quickly, removing the guess work from early diagnosis of upper respiratory infections. By testing saliva, the disposable cartridge will provide early detection for Strep A, Influenza A, Influenza B, Adenovirus and RSV.
Scanadu will introduce all three products to market by the end of 2013.
Creating Your Personal HealthFeed
Scanadu is empowering consumers with medical tools that educate in real time - as well as over time. With the Scanadu mobile app, consumers will be able to track their personal healthfeed to monitor personal vitals and averages and identify health stats and trends over time. This healthfeed will provide consumers with a better understanding of their health and create more informed conversations between patients and their healthcare providers.
“When it comes to health - averages don’t cut it. Vitals change throughout the day and vary from person to person, so it makes no sense to assume we are all the same,” said Dr. Alan Greene, Chief Medical Officer at Scanadu. “Health decision shouldn’t be based on averages, they should be based on a real, accurate and personalized healthfeed of data - which we now have the power to give to the consumer in the palm of their hand.”
Based at NASA-Ames Research Center, Scanadu is using mobile, sensor and social technology to ensure this is the last generation to know so little about their health. Its first products look to disrupt home medicine and will be in market by 2013. Scanadu was founded by Walter de Brouwer in 2010. For more information visit www.Scanadu.com.